会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 11. 发明申请
    • Enzyme Inhibitors
    • 酶抑制剂
    • US20090247507A1
    • 2009-10-01
    • US12158339
    • 2006-12-21
    • Vassilios BavetsiasEdward McDonaldSpyridon Linardopoulos
    • Vassilios BavetsiasEdward McDonaldSpyridon Linardopoulos
    • A61K31/551C07D471/04A61P37/02A61P35/00C12N9/99A61K31/4545A61K31/5377A61K31/496
    • C07D471/04
    • Compounds of formula (I), are aurora kinase inhibitors: wherein X is —N—, —CH2—N—, —CH2—CH—, or —CH—; R1 is a radical of formula (IA) wherein Z is —CH2—, —NH—, -0-, —S(O)— —S—, —S(O)2 or a divalent monocyclic carbocyclic or heterocyclic radical having 3-7 ring atoms; Alk is an optionally substituted divalent C1-C6 alkylene radical; A is hydrogen or an optionally substituted monocyclic carbocyclic or heterocyclic ring having 5-7 ring atoms; r, s and t are independently 0 or 1, provided that when A is hydrogen then at least one of r and s is 1; R2 is halogen, —CN, —CF3, —OCH3, or cyclopropyl; and R3 is a radical of formula (IB) wherein Q is hydrogen or an optionally substituted phenyl or monocyclic heterocyclic ring with 5 or 6 ring atoms; Z&It;1> is —S—, —S(O)—, —S(O)2—, —O—, —SO2NH—, —NHSO2—, NHC(═O)NH, —NH(C═S)NH—, Or —N(R4)—wherein R4 is hydrogen, C1-C3 alkyl, cycloalkyl, or benzyl; and Alk&It;1> and Alk&It;2> are, independently, optionally substituted divalent C1-C3 alkylene radicals; and m, n and p are independently 0 or 1. Data supplied from the esp@cenet datatbase—Worldwide d77
    • 式(I)化合物是极光激酶抑制剂:其中X是-N-,-CH 2 -N,-CH 2 -CH-或-CH-; R1是式(IA)的基团,其中Z是-CH 2 - , - NH - , - O - , - S(O)-S - , - S(O)2或具有3价的二价单环碳环或杂环基 -7环原子; Alk是任选取代的二价C 1 -C 6亚烷基; A是氢或任选取代的具有5-7个环原子的单环碳环或杂环; r,s和t独立地为0或1,条件是当A为氢时,r和s中的至少一个为1; R2是卤素,-CN,-CF3,-OCH3或环丙基; 并且R 3是式(IB)的基团,其中Q是氢或具有5或6个环原子的任选取代的苯基或单环杂环; (O) - , - S(O)2 - , - O - , - SO 2 NH-,-NHSO 2 - ,NHC(-O)NH,-NH(CS)NH- 或-N(R4) - 其中R4是氢,C1-C3烷基,环烷基或苄基; 和Alk&It; 1>和Alk&It; 2>独立地是任选取代的二价C1-C3亚烷基; m,n和p独立为0或1.从esp @ cenet datatbase-Worldwide d77提供的数据
    • 19. 发明授权
    • Trisubstituted purine derivatives
    • 三取代嘌呤衍生物
    • US08592581B2
    • 2013-11-26
    • US12573337
    • 2009-10-05
    • Peter William SheldrakeButrus AtrashSimon GreenEdward McDonaldSheelagh Frame
    • Peter William SheldrakeButrus AtrashSimon GreenEdward McDonaldSheelagh Frame
    • A61K31/52C07D473/16
    • C07D473/16
    • The present invention relates to compounds of formula (I) wherein: R1 and R2 are each independently H, alkyl or haloalkyl; R3 and R4 are each independently H, alkyl, haloalkyl or aryl; R5 is alkyl or cycloalkyl or cycloalkyl-alkyl, each of which may be optionally substituted with one or more OH groups; R6 is selected from cyclopropylamino, cyclopropylmethylamino, cyclobutylamino, cyclobutylmethylamino and where one of X, Y and Z is N and the remainder are CR9; R7, R8 and each R9 are independently H, alkyl or haloalkyl, wherein at least one of R7, R8 and each R9 is other than H. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula (I), and the use of said compounds in treating proliferative disorders, viral disorders, stroke, alopecia, CNS disorders, neurodegenerative disorders, or diabetes.
    • 本发明涉及式(I)化合物,其中:R 1和R 2各自独立地为H,烷基或卤代烷基; R 3和R 4各自独立地为H,烷基,卤代烷基或芳基; R5是烷基或环烷基或环烷基 - 烷基,其各自可以任选地被一个或多个OH基团取代; R 6选自环丙基氨基,环丙基甲基氨基,环丁基氨基,环丁基甲基氨基,其中X,Y和Z中的一个为N,其余为CR 9; R 7,R 8和R 9各自独立地为H,烷基或卤代烷基,其中R 7,R 8和R 9中的至少一个不是H.本发明的另一方面涉及包含式(I)化合物的药物组合物, 使用所述化合物治疗增殖性疾病,病毒性疾病,中风,脱发,中枢神经系统疾病,神经变性疾病或糖尿病。
    • 20. 发明授权
    • Substituted 5-membered ring compounds and their use
    • 取代的5元环化合物及其用途
    • US07728016B2
    • 2010-06-01
    • US10561969
    • 2004-06-24
    • Kwai Ming CheungBrian William DymockEdward McDonaldMartin James Drysdale
    • Kwai Ming CheungBrian William DymockEdward McDonaldMartin James Drysdale
    • A61K31/4192C07D249/06
    • A61K31/4196A61K31/4192A61K31/427A61K31/433
    • Compound of a compound of formula (I) or a salt, N-oxide, hydrate or solvate thereof, in the preparation of a composition for inhibition of HSP90 activity: wherein ring A is an aromatic or non-aromatic carbocyclic or heterocyclic ring having 5 ring atoms, for example 1,2,3-triazolyl or a 1,2,4-triazolyl or a tetrazolyl ring; and R1 R2 R3 are as defined in the specification are inhibitors of HSP90 and therefore of use in the treatment of, for example, cancers, viral disease, inflammatory diseases such as rheumatoid arthritis, asthma, multiple sclerosis, Type I diabetes, lupus, psoriasis and inflammatory bowel disease; cystic fibrosis angiogenesis-related disease such as diabetic retinopathy, haemangiomas, and endometriosis; or for protection of normal cells against chemotherapy-induced toxicity; or diseases where failure to undergo apoptosis is an underlying factor, or protection from hypoxia-ischemic injury due to elevation of Hsp70 in the heart and brain; scrapie/CJD, Huntingdon's and Alzheimer's disease.
    • 式(I)化合物或其盐,N-氧化物,水合物或溶剂化物的化合物在制备抑制HSP90活性的组合物中的用途:其中环A是具有5个或更多个碳原子的芳族或非芳族碳环或杂环 环原子,例如1,2,3-三唑基或1,2,4-三唑基或四唑基环; 和R1 R2 R3如本说明书中所定义的是HSP90的抑制剂,因此用于治疗例如癌症,病毒性疾病,炎性疾病如类风湿性关节炎,哮喘,多发性硬化,I型糖尿病,狼疮,牛皮癣 和炎症性肠病; 囊性纤维化血管生成相关疾病如糖尿病性视网膜病变,血管瘤和子宫内膜异位症; 或用于保护正常细胞免受化疗诱导的毒性; 或未能进行细胞凋亡的疾病是潜在的因素,或由于心脏和脑中Hsp70的升高而保护缺氧缺血性损伤; 瘙痒病/ CJD,亨廷顿氏症和阿尔茨海默病。